Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. News related to Oragenics often centers on the progress of its lead intranasal drug candidate, ONP-002, which is being advanced for the treatment of concussion and mild traumatic brain injury, as well as broader developments in its intranasal platform for neurological disorders.
Investors and followers of OGEN can use this news feed to track company announcements about clinical milestones, such as Human Research Ethics Committee approval in Australia, selection of Southern Star Research as Clinical Research Organization for the Phase IIa ONP-002 trial, and updates on anticipated Phase IIa and Phase IIb studies. Oragenics’ press releases also cover manufacturing and operational agreements, including its cGMP production partnership with Sterling Pharma Solutions to supply ONP-002 for clinical development.
Another recurring theme in Oragenics news is strategic and financial activity. The company has reported public offerings of Series H Convertible Preferred Stock and Warrants, at-the-market equity sales, and related steps taken to restore and maintain compliance with NYSE American stockholders’ equity requirements. These updates provide context on how Oragenics is funding its clinical programs and strengthening its balance sheet.
In addition, Oragenics issues news about pipeline expansion and partnerships, including its collaboration with Receptor.AI, an artificial intelligence–driven drug profiling company, aimed at accelerating development of additional pharmaceutical candidates for brain health. The company also announces its participation in industry conferences and investor events, where it presents its intranasal concussion program and broader neurological platform. Readers interested in OGEN can follow this page for ongoing disclosures directly sourced from company press releases and related regulatory communications.
Oragenics, Inc. (NYSE American: OGEN) announced positive results from a hamster challenge study assessing its SARS-CoV-2 vaccine candidate. Both intranasal and intramuscular formulations demonstrated robust immune responses, successfully reducing viral loads to undetectable levels. The company plans to focus on the intranasal delivery route, citing advantages such as ease of distribution and potential for mucosal immunity. This study will support their Investigational New Drug filing to the FDA, expected in Q2 2022, advancing the program into human clinical trials.
Oragenics, Inc. (NYSE American: OGEN) announced the adjournment of its Annual Meeting of Shareholders originally scheduled for November 22, 2021, due to insufficient quorum. The meeting will reconvene on January 25, 2022, at 4:00 p.m. ET, to allow more time for shareholders to vote on proposals detailed in the proxy statement filed with the SEC on October 13, 2021. Currently, only 40% of shares are represented by proxy. Shareholders are encouraged to vote by January 24, 2022, at 11:59 p.m. ET. The company is enlisting Alliance Advisors to help secure the necessary votes.
Oragenics (NYSE American: OGEN) has been awarded a $250,000 small business innovation research grant for its lantibiotics research. The funding will support the development of novel antibiotics addressing ESKAPE pathogens, which are increasingly resistant to existing treatments. The grant, part of the National Institutes of Health's initiative, emerges amidst rising antibiotic resistance and aims to enhance the company’s R&D capabilities in collaboration with Florida International University. Executive Chairman Frederick W. Telling expressed optimism about the potential of lantibiotics in combating life-threatening infections.
Oragenics, Inc. (NYSE American: OGEN) has launched a study to evaluate the immunogenicity and viral load reduction of its SARS-CoV-2 vaccine candidate, Terra CoV-2, using novel adjuvants for both intranasal and intramuscular formulations. The hamster challenge study aims to assess cross-neutralization against COVID-19 variants, with results expected in November. These findings will contribute to the Investigational New Drug filing with the FDA, anticipated in Q1 2022, to advance into human clinical trials.
Oragenics, Inc. (NYSE American: OGEN) announces promising results in its COVID-19 vaccine development, utilizing a stabilized pre-fusion spike protein trimer that generates neutralizing antibodies in mice. Collaborating with NIH, the company is advancing candidates for a hamster viral challenge study, set to begin this month. OGEN plans to submit an IND application for its Terra CoV-2 vaccine in Q1 2022, confident in the immunogenicity of its novel adjuvants. The firm aims to improve vaccine development speed, addressing potential COVID-19 variants amidst ongoing public health challenges.
Oragenics, Inc. (AMEX: OGEN) announced the adjournment of its reconvened annual meeting of shareholders on August 23, 2021, due to a lack of quorum. A new date for the annual meeting will be established, along with a new record date, as the previous one from May 5, 2021 is no longer valid. Oragenics focuses on combating infectious diseases, with its lead product, Terra CoV-2, aimed at preventing COVID-19 and its variants.
Oragenics, Inc. (NYSE American: OGEN) has entered a licensing agreement with the National Research Council of Canada to develop next-generation vaccines against SARS-CoV-2 and its variants. The collaboration leverages NRC technologies, enhancing the speed of cell line production for spike protein antigens from six months to six to eight weeks. The company has initiated preclinical studies and aims to advance vaccine candidates rapidly. This strategy may position Oragenics competitively against existing vaccines, particularly with additional options like intranasal administration.
Oragenics, Inc. (NYSE American: OGEN) has announced that its annual shareholder meeting, convened on June 30, 2021, was adjourned due to a lack of quorum. The meeting is rescheduled for August 23, 2021, at 4:00 p.m. The Company continues to solicit votes to meet the quorum requirement of a majority of shares. Currently, only 40% of the shares are represented by proxy. Shareholders of record as of May 5, 2021, are urged to vote by August 22, 2021. If quorum is not reached, further adjournment may incur additional costs.
Oragenics (NYSE American: OGEN) affirms its commitment to advancing its business strategy following the resignation of CEO Alan Joslyn. Executive Chairman Frederick W. Telling will take a more active management role. The company is focused on developing the Terra CoV-2 vaccine to combat COVID-19 and antibiotic resistance through its lantibiotics program. Oragenics has a strong leadership team and has recently raised nearly $22 million to support its initiatives, which positions it to continue operations well into 2022.
Oragenics, Inc. (NYSE American: OGEN) announced the resignation of Dr. Alan Joslyn as CEO and President, effective May 2, 2021. Dr. Frederick Telling transitions to Executive Chairman, while CFO Mr. Sullivan takes on the role of interim principal executive officer. The Board will guide the company in the interim as they seek a new CEO to lead the Terra CoV-2 vaccine development. Oragenics focuses on creating a vaccine to combat COVID-19 and developing new antibiotics. The company expresses gratitude for Dr. Joslyn's contributions and remains committed to future growth.